77 related articles for article (PubMed ID: 8874178)
1. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells.
Raelson JV; Nervi C; Rosenauer A; Benedetti L; Monczak Y; Pearson M; Pelicci PG; Miller WH
Blood; 1996 Oct; 88(8):2826-32. PubMed ID: 8874178
[TBL] [Abstract][Full Text] [Related]
2. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
[TBL] [Abstract][Full Text] [Related]
3. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.
Zhu J; Koken MH; Quignon F; Chelbi-Alix MK; Degos L; Wang ZY; Chen Z; de Thé H
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3978-83. PubMed ID: 9108090
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.
Schinke C; Goel S; Bhagat TD; Zhou L; Mo Y; Gallagher R; Kabalka GW; Platanias LC; Verma A; Das B
Leuk Lymphoma; 2010 Jun; 51(6):1108-14. PubMed ID: 20536349
[TBL] [Abstract][Full Text] [Related]
5. NLS‑RARα modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway.
Song H; Li L; Zhong L; Yang R; Jiang K; Yang X; Liu B
Mol Med Rep; 2016 Dec; 14(6):5495-5500. PubMed ID: 27840989
[TBL] [Abstract][Full Text] [Related]
6. Critical role of MXRA7 in differentiation blockade in human acute promyelocytic leukemia cells.
Sun Z; Lin D; Shen Y; Ma K; Wang B; Liu H; Chen S; Wu D; Wang Y
Exp Hematol; 2023; 125-126():45-54. PubMed ID: 37419299
[TBL] [Abstract][Full Text] [Related]
7. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.
Alcalay M; Tomassoni L; Colombo E; Stoldt S; Grignani F; Fagioli M; Szekely L; Helin K; Pelicci PG
Mol Cell Biol; 1998 Feb; 18(2):1084-93. PubMed ID: 9448006
[TBL] [Abstract][Full Text] [Related]
8. A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia.
Uy GL; Lane AA; Welch JS; Grieselhuber NR; Payton JE; Ley TJ
Blood; 2010 Nov; 116(18):3604-10. PubMed ID: 20647568
[TBL] [Abstract][Full Text] [Related]
9. PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.
Katerndahl CDS; Rogers ORS; Day RB; Xu Z; Helton NM; Ramakrishnan SM; Miller CA; Ley TJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317690121. PubMed ID: 38648485
[TBL] [Abstract][Full Text] [Related]
10. History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies.
Bercier P; de Thé H
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611029
[TBL] [Abstract][Full Text] [Related]
11. Genetic fusions favor tumorigenesis through degron loss in oncogenes.
Liu J; Tokheim C; Lee JD; Gan W; North BJ; Liu XS; Pandolfi PP; Wei W
Nat Commun; 2021 Nov; 12(1):6704. PubMed ID: 34795215
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine in the treatment stratification of AML patients: challenges and progress.
Lohse I; Statz-Geary K; Brothers SP; Wahlestedt C
Oncotarget; 2018 Dec; 9(102):37790-37797. PubMed ID: 30701032
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation.
Jambrovics K; Uray IP; Keresztessy Z; Keillor JW; Fésüs L; Balajthy Z
Haematologica; 2019 Mar; 104(3):505-515. PubMed ID: 30237268
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)
Holloway RW; Thomas ML; Cohen AM; Bharadwaj AG; Rahman M; Marcato P; Marignani PA; Waisman DM
Cell Death Dis; 2018 Sep; 9(9):920. PubMed ID: 30206209
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.
Singh AA; Petraglia F; Nebbioso A; Yi G; Conte M; Valente S; Mandoli A; Scisciola L; Lindeboom R; Kerstens H; Janssen-Megens EM; Pourfarzad F; Habibi E; Berentsen K; Kim B; Logie C; Heath S; Wierenga ATJ; Clarke L; Flicek P; Jansen JH; Kuijpers T; Yaspo ML; Valle VD; Bernard O; Gut I; Vellenga E; Stunnenberg HG; Mai A; Altucci L; Martens JHA
Oncotarget; 2018 May; 9(39):25647-25660. PubMed ID: 29876014
[TBL] [Abstract][Full Text] [Related]
16. NLS-RARα is a novel transcriptional factor.
Jiang KL; Zhong L; Yang XQ; Ma PP; Wang H; Zhu XY; Liu BZ
Oncol Lett; 2017 Dec; 14(6):7091-7098. PubMed ID: 29344139
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D Receptor Signaling and Cancer.
Campbell MJ; Trump DL
Endocrinol Metab Clin North Am; 2017 Dec; 46(4):1009-1038. PubMed ID: 29080633
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid, CYP26, and drug resistance in the stem cell niche.
Alonso S; Jones RJ; Ghiaur G
Exp Hematol; 2017 Oct; 54():17-25. PubMed ID: 28754309
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.
McCulloch D; Brown C; Iland H
Onco Targets Ther; 2017; 10():1585-1601. PubMed ID: 28352191
[TBL] [Abstract][Full Text] [Related]
20. Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
Huang J; Sun M; Wang Z; Zhang Q; Lou J; Cai Y; Chen W; Du X
Oncotarget; 2016 Nov; 7(44):71974-71986. PubMed ID: 27713127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
